Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - Tobira Therapeutics, Inc. | d908068dex311.htm |
| EX-32.2 - EXHIBIT 32.2 - Tobira Therapeutics, Inc. | d908068dex322.htm |
| EX-31.2 - EXHIBIT 31.2 - Tobira Therapeutics, Inc. | d908068dex312.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Tobira Therapeutics, Inc. | Financial_Report.xls |
| 10-Q - FORM 10-Q - Tobira Therapeutics, Inc. | d908068d10q.htm |
Exhibit 32.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(b)
OF THE SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350
In connection with the Quarterly Report on Form 10-Q of Regado Biosciences, Inc. (the “Company”) for the quarter ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Michael A. Metzger, Chief Executive Officer of the Company, hereby certifies, to the knowledge of the undersigned, pursuant to 18 U.S.C. Section 1350, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: April 29, 2015
| /s/ Michael A. Metzger |
| Michael A. Metzger |
| Chief Executive Officer |
| (Principal Executive Officer) |
This Certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing.
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.